ASXL3 Inhibitors
Chemical inhibitors of ASXL3 function by disrupting the interaction between ASXL3 and histone deacetylases (HDACs), which are crucial for the protein's role in chromatin remodeling and gene expression regulation. Trichostatin A, Vorinostat, Panobinostat, Romidepsin, MGCD0103, Belinostat, Entinostat, Tacedinaline, Valproic Acid, AR-42, Quisinostat, and CUDC-101 are all HDAC inhibitors that alter the acetylation status of histones. These changes in histone acetylation can impair the ability of ASXL3 to modulate chromatin structure effectively. For instance, Trichostatin A and Vorinostat can lead to increased histone acetylation, thus preventing ASXL3 from maintaining chromatin in a configuration that is conducive to its normal function. Panobinostat, as a pan-HDAC inhibitor, further broadens the scope of HDAC inhibition, impacting multiple classes of HDACs that ASXL3 might interact with, leading to a more generalized disruption of its function.
Similarly, Romidepsin's specificity for Class I HDACs can singularly affect the subset of HDACs that are most relevant for ASXL3's activity in certain contexts. MGCD0103 and Belinostat, by inhibiting Class I and IV HDACs, target the enzyme classes that directly interact with ASXL3, leading to a functional impairment of ASXL3's ability to regulate gene expression. Entinostat's selective inhibition of Class I HDACs and Tacedinaline's inhibition of HDACs can also disrupt ASXL3 function by a similar mechanism. Valproic Acid, with its HDAC inhibitory activity, changes histone acetylation states that are critical for ASXL3's role in gene regulation. AR-42 and Quisinostat, by inhibiting HDACs, can disrupt the chromatin remodeling activities of ASXL3, affecting its ability to regulate gene expression. Lastly, CUDC-101's multi-target inhibition profile, including HDACs, suggests that it can impede ASXL3's chromatin-modifying activities, leading to a comprehensive inhibition of ASXL3's functional role within the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase (HDAC) inhibitor. ASXL3 interacts with HDACs as part of a complex involved in chromatin remodeling. By inhibiting HDACs, Trichostatin A can alter the acetylation status of histones, potentially disrupting the ASXL3's ability to properly modulate chromatin structure and gene expression, leading to functional inhibition of ASXL3. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another HDAC inhibitor, could impede ASXL3 function in a similar manner to Trichostatin A. By preventing the deacetylation of histones, Vorinostat can interfere with the chromatin remodeling activities of ASXL3, thereby inhibiting its function in gene expression regulation. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
Panobinostat is a potent pan-HDAC inhibitor that, by blocking the activity of HDACs, could disrupt the interaction of ASXL3 with these enzymes, leading to a functional impairment of ASXL3 in chromatin modification and gene regulation. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin specifically inhibits Class I HDACs. Since ASXL3 is part of a complex involving HDACs, inhibition of these enzymes by Romidepsin can disrupt ASXL3's role in the epigenetic regulation of gene expression, thereby inhibiting its function. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
MGCD0103 (Mocetinostat) is a Class I and IV HDAC inhibitor. Inhibition of these specific HDAC classes can disrupt the interaction between ASXL3 and HDACs, hindering ASXL3's ability to modulate chromatin and gene expression, which would result in functional inhibition of ASXL3. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is a HDAC inhibitor that would inhibit ASXL3 by disrupting the chromatin remodeling complex it is a part of, affecting the acetylation of histones and thus the ability of ASXL3 to exert its regulatory functions on gene expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat selectively inhibits Class I HDACs. Through its action on HDACs, it would impair the ability of ASXL3 to interact with these enzymes, leading to a functional inhibition of ASXL3's role in chromatin modification and gene regulation. | ||||||
CI 994 | 112522-64-2 | sc-205245 sc-205245A | 10 mg 50 mg | $99.00 $536.00 | 1 | |
Tacedinaline is a HDAC inhibitor that would inhibit ASXL3 by preventing the deacetylation of histones, potentially disrupting the chromatin remodeling functions of ASXL3 and thereby inhibiting its role in gene expression. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic Acid is an HDAC inhibitor that can disrupt the function of ASXL3 by altering histone acetylation and thus chromatin structure, which is central to ASXL3's role in gene regulation. | ||||||
(S)-HDAC-42 | 935881-37-1 | sc-296364 sc-296364A | 1 mg 5 mg | $96.00 $417.00 | ||
AR-42 is a HDAC inhibitor that would hinder ASXL3's function by disrupting its interaction with HDACs, affecting the chromatin remodeling process and consequently the ability of ASXL3 to regulate gene expression. | ||||||